Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on RNA Therapy Clinical Trials Market 

5.1. COVID-19 Landscape: RNA Therapy Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global RNA Therapy Clinical Trials Market, By Modality

8.1. RNA Therapy Clinical Trials Market, by Modality, 2024-2033

8.1.1 RNA Interference

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Antisense Therapy

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Messenger RNA

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Oligonucleotide, Non-antisense, Non-RNAi

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase

9.1. RNA Therapy Clinical Trials Market, by Clinical Trials Phase, 2024-2033

9.1.1. Phase I

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Phase II

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Phase III

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Phase IV

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global RNA Therapy Clinical Trials Market, By Therapeutic Areas 

10.1. RNA Therapy Clinical Trials Market, by Therapeutic Areas, 2024-2033

10.1.1. Rare Diseases

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Anti-infective

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Anticancer

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Neurological

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Alimentary/Metabolic

10.1.5.1. Market Revenue and Forecast (2021-2033)

10.1.6. Musculoskeletal

10.1.6.1. Market Revenue and Forecast (2021-2033)

10.1.7. Cardiovascular Respiratory

10.1.7.1. Market Revenue and Forecast (2021-2033)

10.1.8. Sensory

10.1.8.1. Market Revenue and Forecast (2021-2033)

10.1.9. Others

10.1.9.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global RNA Therapy Clinical Trials Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Modality (2021-2033)

11.1.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.1.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Modality (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Modality (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Modality (2021-2033)

11.2.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.2.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Modality (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Modality (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Modality (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Modality (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Modality (2021-2033)

11.3.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.3.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Modality (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Modality (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Modality (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Modality (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Modality (2021-2033)

11.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Modality (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Modality (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Modality (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Modality (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Modality (2021-2033)

11.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Modality (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Modality (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)

Chapter 12. Company Profiles

12.1. IQVIA

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. ICON Plc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Laboratory Corporation of America Holdings

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Charles River Laboratories International, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. PAREXEL International Corp.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Syneos Health

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Medpace Holdings, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. PPD Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Novotech

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Veristat, LLC.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms